Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Prior treatment

• Have a prior or planned surgical treatment for obesity.
• Have any prior use of ixekizumab or tirzepatide.
• Have a previous failure or intolerance to an interleukin 17 inhibitor (IL-17i) or glucagon-like peptide 1 (GLP-1) receptor agonists.

Other illness

• Medical Conditions
• Have Type 1 Diabetes Mellitus (T1DM).
• Have insulin-treated Type 2 Diabetes Mellitus (T2DM).
• Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.
• Have active, or a history of inflammatory bowel disease (Crohn's or ulcerative colitis).
• Have a diagnosis or history of malignant disease within the 5 years prior to randomization, with the following exceptions:
  • basal cell or squamous epithelial carcinomas of the skin that have been resected, with no evidence of metastatic disease for 3 years.
  • cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to randomization.
• Have serious disorder or illness other than PsO.
• Have a history of chronic or acute pancreatitis.

• Have a diagnosis of moderate-to-severe plaque psoriasis (PsO) for at least 6 months.
• Have both a Static Physician's Global Assessment (sPGA) score of ≥3 and a Psoriasis Area and Severity Index (PASI) ≥12.
• Have ≥10% body surface area (BSA) involvement.
• Have obesity, body mass index of ≥30 kilograms per meter squared (BMI ≥30 kg/m²) or overweight (BMI ≥27 to \<30 kg/m²) in the presence of at least 1 of these weight-related comorbid conditions (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2DM).